The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
The metabolism of triglyceride-rich lipoproteins revisited: New players, new insight
Open accessAbstract
Peripheral lipoprotein lipase (LPL)-mediated lipolysis of triglycerides is the first step in chylomicron/VLDL clearance involving heparan sulfate proteoglycans (HSPGs) displayed at the cell surface of the capillaries in adipose tissue, heart and skeletal muscle. The newly generated chylomicron remnant particles are then cleared by the liver, whereas VLDL remnant particles are either further modified, through the action of hepatic lipase (HL) and cholesteryl ester transfer protein (CETP), into LDL particles or alternatively directly cleared by the liver. Two proteins, lipase maturation factor 1 (LMF1) and glycosylphosphatidylinositol-anchored high density lipoprotein binding protein 1 (GPIHBP1), have been recently identified and have revised our current understanding of LPL maturation and LPL-mediated lipolysis. Moreover, new insights have been gained with respect to hepatic remnant clearance using genetically modified mice targeting the sulfation of HSPGs and even deletion of the most abundant heparan sulfate proteoglycan: syndecan-1. In this review, we will provide an overview of novel data on both peripheral TG hydrolysis and hepatic remnant clearance that will improve our knowledge of plasma triglyceride metabolism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nordestgaard, B. G., Benn, M., Schnohr, P., & Tybjærg-Hansen, A. (2007) · JAMA · doi:10.1001/jama.298.3.299 · Cited by 2,058
Heparan sulphate proteoglycans fine-tune mammalian physiology
Bishop, J. R., Schuksz, M., & Esko, J. D. (2007) · Nature · doi:10.1038/nature05817 · Cited by 1,631
Order Out of Chaos: Assembly of Ligand Binding Sites in Heparan Sulfate
Esko, J. D., & Selleck, S. B. (2002) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.71.110601.135458 · Cited by 1,495
Rohlmann, A., Gotthardt, M., Hammer, R. E., & Herz, J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1240 · Cited by 455 · cited 1×
“[68] The contribution of LRP1 in remnant clearance has been demonstrated by Rohlmann et al.[28,69] Defective remnant clearance could only be found if both the LDLr and LRP1 were silenced.”
BackgroundStanford, K. I., Bishop, J. R., Foley, E. M., Gonzales, J. C., Niesman, I. R., Witztum, J. L., & Esko, J. D. (2009) · Journal of Clinical Investigation · doi:10.1172/jci38251 · Cited by 226
MacArthur, J. M., Bishop, J. R., Stanford, K. I., Wang, L., Bensadoun, A., Witztum, J. L., & Esko, J. D. (2007) · Journal of Clinical Investigation · doi:10.1172/jci29154 · Cited by 216
Mahley, R. W., & Huang, Y. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30889 · Cited by 159
Mutation of conserved cysteines in the Ly6 domain of GPIHBP1 in familial chylomicronemia.
Olivecrona, G., Ehrenborg, E., Semb, H., Makoveichuk, E., Lindberg, A., Hayden, M. R., Gin, P., Davies, B. S. J., Weinstein, M. M., Fong, L. G., et al. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m002717 · Cited by 118 · cited 2×
“In line, a family was identified in northern Sweden in which three of the four children, with chylomicronemia, were compound heterozygote for two mutations in the Ly6 domain, p.C65S and p.C68G.[53] All patients showed a delayed LPL release after a heparin challenge, resulting in low levels of postheparin LPL mass and…”
BackgroundObunike, J. C., Lutz, E. P., Li, Z., Paka, L., Katopodis, T., Strickland, D. K., Kozarsky, K. F., Pillarisetti, S., & Goldberg, I. J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008813200 · Cited by 91
The acidic domain of GPIHBP1 is important for the binding of lipoprotein lipase and chylomicrons.
Gin, P., Yin, L., Davies, B. S. J., Weinstein, M. M., Ryan, R. O., Bensadoun, A., Fong, L. G., Young, S. G., & Beigneux, A. P. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m802579200 · Cited by 85 · cited 2×
“In fact, replacement of the acidic residues completely eliminates the capacity of GPIHBP1 to bind LPL and chylomicrons.[50] Moreover, mutations in the heparin-binding domain of both LPL and apo-AV abolished the binding of these proteins to GPIHBP1.”
Background
Research works printed but not linked: 66
- Goldberg, 2001, Lipoprotein lipase: physiology, biochemistry, and molecular biology, Front Biosci, 6, D388, 10.2741/Goldberg · DOI · Paper page
- Bensadoun, 1991, Lipoprotein lipase, Annu Rev Nutr, 11, 217, 10.1146/annurev.nu.11.070191.001245 · DOI
- Olivecrona, 1993, Lipoprotein lipase and hepatic lipase, Curr Opin Lipidol, 4, 187, 10.1097/00041433-199306000-00003 · DOI
- Wang, 2009, Lipoprotein lipase: from gene to obesity, Am J Physiol Endocrinol Metab, 297, E271, 10.1152/ajpendo.90920.2008 · DOI · Paper page
- Williams, 2008, Molecular processes that handle – and mishandle – dietary lipids, J Clin Invest, 118, 3247, 10.1172/JCI35206 · DOI · Paper page
- Braun, 1992, Regulation of the synthesis, processing and translocation of lipoprotein lipase, Biochem J, 287, 337, 10.1042/bj2870337 · DOI · Paper page
- Goldberg, 1996, Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolismand atherogenesis, J Lipid Res, 37, 693, 10.1016/S0022-2275(20)37569-6 · DOI · Paper page
- Williams, 2009, Some things just have to be done in vivo: GPIHBP1, caloric delivery, and the generation of remnant lipoproteins, Arterioscler Thromb Vasc Biol, 29, 792, 10.1161/ATVBAHA.109.187823 · DOI
- Sendak, 1998, Identification of the epitope of a monoclonal antibody that inhibits heparin binding of lipoprotein lipase: new evidence for a carboxyl-terminal heparin-binding domain, J Lipid Res, 39, 633, 10.1016/S0022-2275(20)33301-0 · DOI
- Parthasarathy, 1994, Oligosaccharide sequences of endothelial cell surface heparan sulfate proteoglycan with affinity for lipoprotein lipase, J Biol Chem, 269, 22391, 10.1016/S0021-9258(17)31802-1 · DOI · Paper page
- Osborne, 1985, Studies on inactivation of lipoprotein lipase: role of the dimer to monomer dissociation, Biochemistry, 24, 5606, 10.1021/bi00341a048 · DOI · Paper page
- Franssen, 2008, Role of lipoprotein lipase in triglycerdie metabolism: potential therapeutic target, Future Lipidol, 3, 385, 10.2217/17460875.3.4.385 · DOI
- Oliva, 2005, Inherited apolipoprotein A-V deficiency in severe hypertriglyceridemia, Arterioscler Thromb Vasc Biol, 25, 411, 10.1161/01.ATV.0000153087.36428.dd · DOI · Paper page
- Pullinger, 2008, An apolipoprotein A-V gene SNP is associated with marked hypertriglyceridemia among Asian-American patients, J Lipid Res, 49, 1846, 10.1194/jlr.P800011-JLR200 · DOI
- Talmud, 2007, Rare APOA5 mutations – clinical consequences, metabolic and functional effects: an ENID review, Atherosclerosis, 194, 287, 10.1016/j.atherosclerosis.2006.12.010 · DOI
- Vaessen, 2006, Apolipoprotein A-V, triglycerides and risk of coronary artery disease: the prospective Epic-Norfolk Population Study, J Lipid Res, 47, 2064, 10.1194/jlr.M600233-JLR200 · DOI
- Dallinga-Thie, 2006, Plasma apolipoprotein A5 and triglycerides in type 2 diabetes, Diabetologia, 49, 1505, 10.1007/s00125-006-0261-0 · DOI
- Sukonina, 2006, Angiopoietin-like protein 4 converts lipoprotein lipase to inactive monomers and modulates lipase activity in adipose tissue, Proc Natl Acad Sci USA, 103, 17450, 10.1073/pnas.0604026103 · DOI · Paper page
- Romeo, 2009, Rare loss-of-function mutations in ANGPTL family members contribute to plasma triglyceride levels in humans, J Clin Invest, 119, 70
- Sonnenburg, 2009, Glycosylphosphatidylinositol-anchored HDL-binding protein stabilizes lipoprotein lipase and prevents its inhibition by angiopoietin-like 3 and angiopoietin-like 4, J Lipid Res, 50, 2421, 10.1194/jlr.M900145-JLR200 · DOI · Paper page
- Peterfy, 2007, Mutations in LMF1 cause combined lipase deficiency and severe hypertriglyceridemia, Nat Genet, 39, 1483, 10.1038/ng.2007.24 · DOI · Paper page
- Beigneux, 2007, Glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 plays a critical role in the lipolytic processing of chylomicrons, Cell Metab, 5, 279, 10.1016/j.cmet.2007.02.002 · DOI · Paper page
- Beigneux, 2009, Chylomicronemia with a mutant GPIHBP1 (Q115P) that cannot bind lipoprotein lipase, Arterioscler Thromb Vasc Biol, 29, 956, 10.1161/ATVBAHA.109.186577 · DOI · Paper page
- Bishop, 2008, Heparan sulfate proteoglycans and triglyceride-rich lipoprotein metabolism, Curr Opin Lipidol, 19, 307, 10.1097/MOL.0b013e3282feec2d · DOI · Paper page
- Mahley, 1999, Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E, J Lipid Res, 40, 1, 10.1016/S0022-2275(20)33334-4 · DOI · Paper page
- Fuki, 1997, The syndecan family of proteoglycans. Novel receptors mediating internalization of atherogenic lipoproteins in vitro, J Clin Invest, 100, 1611, 10.1172/JCI119685 · DOI · Paper page
- Mortimer, 1997, Use of gene-manipulated models to study the physiology of lipid transport, Clin Exp Pharmacol Physiol, 24, 281, 10.1111/j.1440-1681.1997.tb01820.x · DOI
- Paterniti, 1983, Combined lipase deficiency (cld): a lethal mutation on chromosome 17 of the mouse, Science, 221, 167, 10.1126/science.6857276 · DOI
- Olivecrona, 1986, Effect of combined lipase deficiency (cld/cld) on hepatic and lipoprotein lipase activities in liver and plasma of newborn mice, Biochim Biophys Acta, 876, 243, 10.1016/0005-2760(86)90280-8 · DOI
- Scow, 1998, Combined lipase deficiency (cld/cld) in mice affects differently post-translational processing of lipoprotein lipase, hepatic lipase and pancreatic lipase, Chem Phys Lipids, 93, 149, 10.1016/S0009-3084(98)00039-5 · DOI
- Reue, 1996, Naturally occurring mutations in mice affecting lipid transport and metabolism, J Lipid Res, 37, 1387, 10.1016/S0022-2275(20)39126-4 · DOI
- Doolittle, 2009, Lipase maturation factor 1 (Lmf1): membrane topology and interaction with lipase proteins in the endoplasmic reticulum, J Biol Chem, 284, 33623, 10.1074/jbc.M109.049395 · DOI
- Cefalu, 2009, Novel LMF1 nonsense mutation in a patient with severe hypertriglyceridemia, J Clin Endocrinol Metab, 94, 4584, 10.1210/jc.2009-0594 · DOI
- Yin, 2009, A quantitative assay measuring the function of lipase maturation factor 1 (Lmf1), J Lipid Res, 50, 2265, 10.1194/jlr.M900196-JLR200 · doi:10.1194/jlr.m900196-jlr200
- Young, 2007, GPIHBP1: an endothelial cell molecule important for the lipolytic processing of chylomicrons, Curr Opin Lipidol, 18, 389, 10.1097/MOL.0b013e3281527914 · DOI
- Ioka, 2003, Expression cloning and characterization of a novel glycosylphosphatidylinositol-anchored high density lipoprotein-binding protein, GPI-HBP1, J Biol Chem, 278, 7344, 10.1074/jbc.M211932200 · DOI
- Ploug, 1994, Structure–function relationships in the receptor for urokinase-type plasminogen activator. Comparison to other members of the Ly-6 family and snake venom alpha-neurotoxins, FEBS Lett, 349, 163, 10.1016/0014-5793(94)00674-1 · DOI · Paper page
- Beigneux, 2008, Glycosylation of Asn-76 in mouse GPIHBP1 is critical for its appearance on the cell surface and the binding of chylomicrons and lipoprotein lipase, J Lipid Res, 49, 1312, 10.1194/jlr.M700593-JLR200 · DOI
- Lookene, 2005, Apolipoprotein A-V–heparin interactions: implications for plasma lipoprotein metabolism, J Biol Chem, 280, 25383, 10.1074/jbc.M501589200 · DOI
- Sendak, 1998, Identification of a heparin-binding domain in the distal carboxyl-terminal region of lipoprotein lipase by site-directed mutagenesis, J Lipid Res, 39, 1310, 10.1016/S0022-2275(20)32557-8 · DOI
- Hill, 1998, Subdomain chimeras of hepatic lipase and lipoprotein lipase – localization of heparin and cofactor binding, J Biol Chem, 273, 30979, 10.1074/jbc.273.47.30979 · DOI
- Lookene, 2000, Contribution of the carboxy-terminal domain of lipoprotein lipase to interaction with heparin and lipoproteins, Biochem Biophys Res Commun, 271, 15, 10.1006/bbrc.2000.2530 · DOI
- Beg, 1998, Analysis of heparin-binding sites in human lipoprotein lipase using synthetic peptides, J Protein Chem, 17, 807, 10.1023/A:1020730418999 · doi:10.1023/a:1020730418999
- Hussain, 2000, High affinity binding between lipoprotein lipase and lipoproteins involves multiple ionic and hydrophobic interactions, does not require enzyme activity, and is modulated by glycosaminoglycans, J Biol Chem, 275, 29324, 10.1074/jbc.M005317200 · DOI
- Dallinga-Thie, 2009, Two mutations in GPIHBP1 cause severe chylomicronemia and provide evidence for a critical role of GPIHBP1 in human triglyceride metabolism, Arterioscler Thromb Vasc Biol, 29, e10
- Franssen R, Young SG, Peelman F, et al. Chylomicronemia with low postheparin lipoprotein lipase levels in the setting of GPIHBP1 defects. Circ Cardiovasc genet 2010, accepted manuscript. · DOI
- Beigneux, 2009, Highly conserved cysteines within the Ly6 domain of GPIHBP1 are crucial for the binding of lipoprotein lipase, J Biol Chem, 284, 30240, 10.1074/jbc.M109.046391 · DOI
- Korn, 1955, Clearing factor, a heparin-activated lipoprotein lipase. II. Substrate specificity and activation of coconut oil, J Biol Chem, 215, 15, 10.1016/S0021-9258(18)66012-0 · DOI · Paper page
- Babirek, 1989, Detection and characterization of the heterozygote state for lipoprotein lipase deficiency, Arterioscler Thromb, 9, 326, 10.1161/01.ATV.9.3.326 · DOI · Paper page
- Weinstein, 2008, Abnormal patterns of lipoprotein lipase release into the plasma in GPIHBP1-deficient mice, J Biol Chem, 283, 34511, 10.1074/jbc.M806067200 · DOI · Paper page
- Wang, 2005, Endothelial heparan sulfate deficiency impairs l-selectin- and chemokine-mediated neutrophil trafficking during inflammatory responses, Nat Immunol, 6, 902, 10.1038/ni1233 · DOI · Paper page
- Zhang, 2008, Spontaneous atherosclerosis in aged lipoprotein lipase-deficient mice with severe hypertriglyceridemia on a normal chow diet, Circ Res, 102, 250, 10.1161/CIRCRESAHA.107.156554 · DOI · Paper page
- Heeren, 2006, Apolipoprotein E recycling: implications for dyslipidemia and atherosclerosis, Arterioscler Thromb Vasc Biol, 26, 442, 10.1161/01.ATV.0000201282.64751.47 · DOI · Paper page
- Herz, 1995, Initial hepatic removal of chylomicron remnants is unaffected but endocytosis is delayed in mice lacking the low density lipoprotein receptor, Proc Natl Acad Sci USA, 92, 4611, 10.1073/pnas.92.10.4611 · DOI
- Rubinsztein, 1990, Chylomicron remnant clearance from the plasma is normal in familial hypercholesterolemic homozygotes with defined receptor defects, J Clin Invest, 86, 1306, 10.1172/JCI114839 · DOI · Paper page
- Kita, 1982, Hepatic uptake of chylomicron remnants in WHHL rabbits: a mechanism genetically distinct from the low density lipoprotein receptor, Proc Natl Acad Sci USA, 79, 3623, 10.1073/pnas.79.11.3623 · DOI · Paper page
- Jones, 2007, Disruption of LDL but not VLDL clearance in autosomal recessive hypercholesterolemia, J Clin Invest, 117, 165, 10.1172/JCI29415 · DOI · Paper page
- Gordts, 2009, Inactivation of the LRP1 intracellular NPxYxxL motif in LDLR-deficient mice enhances postprandial dyslipidemia and atherosclerosis, Arterioscler Thromb Vasc Biol, 29, 1258, 10.1161/ATVBAHA.109.192211 · DOI
- Laatsch, 2009, Insulin stimulates hepatic low density lipoprotein receptor-related protein 1 (LRP1) to increase postprandial lipoprotein clearance, Atherosclerosis, 204, 105, 10.1016/j.atherosclerosis.2008.07.046 · DOI
- Stanford, 2009, Syndecan-1, the primary heparan sulfate proteoglycan mediating hepatic triglyceride-rich lipoprotein clearance in vivo, J Clin Invest, 119, 3236
- Ji, 1995, Intravenous heparinase inhibits remnant lipoprotein clearance from the plasma and uptake by the liver: in vivo role of heparan sulfate proteoglycans, J Lipid Res, 36, 583, 10.1016/S0022-2275(20)39892-8 · DOI
- Stanford, 2010, Heparan sulfate 2-O-sulfotransferase is required for triglyceride-rich lipoprotein clearance, J Biol Chem, 285, 286, 10.1074/jbc.M109.063701 · DOI
- Kersten, 2009, Caloric restriction and exercise increase plasma ANGPTL4 levels in humans via elevated free fatty acids, Arterioscler Thromb Vasc Biol, 29, 969, 10.1161/ATVBAHA.108.182147 · DOI · Paper page
- Kjaergaard, 2008, Structure and ligand interactions of the urokinase receptor (uPAR), Front Biosci, 13, 5441, 10.2741/3092 · DOI
- Jacobsen, 2008, The urokinase receptor and its structural homologue C4.4A in human cancer: expression, prognosis and pharmacological inhibition, Curr Med Chem, 15, 2559, 10.2174/092986708785909012 · DOI
- Galat, 2008, The three-fingered protein domain of the human genome, Cell Mol Life Sci, 65, 3481, 10.1007/s00018-008-8473-8 · DOI
Cited by
Triglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association
Miller, M., Stone, N. J., Ballantyne, C., Bittner, V., Criqui, M. H., Ginsberg, H. N., Goldberg, A. C., Howard, W. J., Jacobson, M. S., Kris-Etherton, P. M., et al. (2011) · Circulation · doi:10.1161/cir.0b013e3182160726 · Cited by 1,871
Dyslipidemia in obesity: Mechanisms and potential targets
Klop, B., Elte, J., & Cabezas, M. (2013) · Nutrients · doi:10.3390/nu5041218 · Cited by 1,665
“LPL serves as the docking station for chylomicrons and VLDL for adherence to the endothelium via glycosyl-phosphatidylinositol-anchored high-density-binding protein 1 (GPIHBP1), which is present on the luminal side of the endothelium [14–16].”
BackgroundDegradation of the endothelial glycocalyx in clinical settings: searching for the sheddases
Becker, B. F., Jacob, M., Leipert, S., Salmon, A. H. J., & Chappell, D. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12629 · Cited by 464
New insights into the pathophysiology of dyslipidemia in type 2 diabetes
Taskinen, M.-R., & Borén, J. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.01.039 · Cited by 440
Phosphatidylcholine biosynthesis and lipoprotein metabolism
Cole, L. K., Vance, J. E., & Vance, D. E. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2011.09.009 · Cited by 436
Metadata
- Authors
- Dallinga-Thie, G. M., Franssen, R., Mooij, H. L., Visser, M. E., Hassing, H. C., Peelman, F., Kastelein, J. J. P., Péterfy, M., & Nieuwdorp, M.
- Venue
- Atherosclerosis
- Publisher
- Elsevier BV
- Published
- 2010-07
- Volume
- 211
- Issue
- 1
- Pages
- 1-8
- ISSN
- 0021-9150 (ISSN-L)
- OpenAlex
- W2165307225
- Cited by
- 181
- References
- 11
- FWCI
- 9.10
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Funders
- Dutch Heart Association (2008-070B)
- Dutch Government ZonMW-VENI Grant 2008 (016.096.044)
- National Institutes of Health Grant (HL24841)
- Cedars-Sinai Medical Center
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The metabolism of triglyceride-rich lipoproteins revisited: New players, new insight. https://app.cochat.ai/papers/10.1016/j.atherosclerosis.2009.12.027
- The paper
- Dallinga-Thie, G. M., Franssen, R., Mooij, H. L., Visser, M. E., Hassing, H. C., Peelman, F., Kastelein, J. J. P., Péterfy, M., & Nieuwdorp, M. (2010). The metabolism of triglyceride-rich lipoproteins revisited: New players, new insight. Atherosclerosis. https://doi.org/10.1016/j.atherosclerosis.2009.12.027
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.